AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today the commercial launch of its CE-IVD Quantidex™ BCR-ABL IS CMR Kit for monitoring BCR-ABL1 transcript levels in patients with Chronic Myeloid Leukemia (CML). Asuragen will introduce the assay at the European Hematology Association (EHA) 20th Annual Congress in Vienna, Austria, June 11-14th, 2015. The Quantidex™ BCR-ABL IS CMR Kit represents an improvement to existing tests by attaining a sensitivity of MR4.7 (0.002% IS) while also allowing direct reporting on the International Scale (IS).
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
